MCL1 and non-small cell lung carcinoma: The DNA methyltransferase inhibitor decitabine synergized with venetoclax in producing a strong therapeutic effect against NSCLC without normal tissue toxicities, one mechanism of which was epigenetically targeting the FBW7/MCL-1 pathway [148].